drugset / Trial / NCT06838910
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy. The purpose of this study is to evaluate the safety and efficacy of tislelizumab combined with anlotinib as second-line in thymoma and thymic carcinoma.
Timeline
- Start
- 2025-03-31
- Primary completion
- 2026-12
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | — |
| Subject | Catequentinib | Small molecule | 10 mg | — |
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |